【摘要】 目的:探讨替吉奥（S-1）联合奥沙利铂用于中晚期原发性肝癌（HCC）患者的疗效及安全性。方法:回顾2015年1月至2016年12月于宿州市立医院肿瘤内科收治的56例中晚期HCC患者的临床资料,将28例采用S-1联合奥沙利铂（SOX方案）治疗的患者标记为观察组,选取28例同期在我院行奥沙利铂联合5-氟尿嘧啶静脉滴注（FOLFOX₄方案）治疗的中晚期HCC患者为对照组。比较两组患者客观有效率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）,总生存期（OS）和不良反应发生情况。结果:两组患者的RR分别为21.43%、25.00%,DCR分别为64.29%、60.71%,PFS分别为5.0（3.97～6.03）个月、5.0（4.14～5.86）个月,OS分别为8.5（6.77～10.23）个月、9.5（8.03～10.97）个月,差异均无统计学意义（P>0.05）。观察组患者Ⅰ～Ⅱ级和Ⅲ～Ⅳ级血液学毒性的发生率分别为25.00%和3.57%,低于对照组的53.57%和10.71%,差异有统计学意义（P<0.05）,但非血液学毒性差异无统计学意义。结论:S-1联合奥沙利铂治疗中晚期HCC的疗效不劣于FOLFOX₄方案,且不良反应降低,值得进一步研究和推广。更多还原

【Abstract】 Objective: To investigate the efficacy and safety of Tiggio(S-1) combined with oxaliplatin in patients with advanced primary liver cancer(HCC). Methods: The clinical data of 56 patients with advanced HCC who were admitted to the Department of Oncology of Suzhou Municipal Hospital from January 2015 to December 2016 were reviewed. 28 patients treated with S-1 combined with oxaliplatin(SOX regimen) were marked as In the observation group, 28 patients with advanced HCC who were treated with oxaliplatin combined with 5-fluorouracil intravenous drip(FOLFOX4 regimen) in our hospital during the same period were selected as the control group. The objective response rate(ORR), disease control rate(DCR), progression-free survival(PFS), overall survival(OS) and occurrence of adverse reactions were compared between the two groups. Results: The RR of the two groups were 21.43% and 25.00%, the DCR was 64.29%, 60.71%, the PFS was 5.0(3.97～6.03) months, 5.0(4.14～5.86) months, and the OS was 8.5(6.77).～10.23) months, 9.5(8.03～10.97) months, the difference was not statistically significant(P>0.05). The incidence of hematological toxicity of grade Ⅰ～Ⅱ and grade Ⅲ～Ⅳ in the observation group were 25.00% and 3.57%, respectively, which were lower than 53.57% and 10.71% in the control group. The difference was statistically significant(P<0.05), but not There was no statistically significant difference in hematological toxicity. Conclusion:The efficacy of S-1 combined with oxaliplatin in the treatment of advanced HCC is not inferior to the FOLFOX4 regimen, and the adverse reactions are reduced. It is worthy of further research and promotion.更多还原